Cargando…
Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength
Inhibition of the major human drug-metabolizing cytochrome P450 3A4 (CYP3A4) by pharmaceuticals and other xenobiotics could lead to toxicity, drug–drug interactions and other adverse effects, as well as pharmacoenhancement. Despite serious clinical implications, the structural basis and attributes r...
Autores principales: | Samuels, Eric R., Sevrioukova, Irina F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830545/ https://www.ncbi.nlm.nih.gov/pubmed/33467005 http://dx.doi.org/10.3390/ijms22020852 |
Ejemplares similares
-
Interaction of CYP3A4 with Rationally Designed Ritonavir Analogues: Impact of Steric Constraints Imposed on the Heme-Ligating Group and the End-Pyridine Attachment
por: Samuels, Eric R., et al.
Publicado: (2022) -
Interaction of CYP3A4 with caffeine: First insights into multiple substrate binding
por: Sevrioukova, Irina F.
Publicado: (2023) -
Structural Basis for the Diminished Ligand Binding and Catalytic Ability of Human Fetal-Specific CYP3A7
por: Sevrioukova, Irina F.
Publicado: (2021) -
Crystal Structure of CYP3A4 Complexed with Fluorol Identifies the Substrate Access Channel as a High-Affinity Ligand Binding Site
por: Sevrioukova, Irina F.
Publicado: (2022) -
Novel approaches for the rational design of PROTAC linkers
por: Zagidullin, Almaz, et al.
Publicado: (2020)